BRIEF published on 04/29/2026 at 13:05, 6 months 7 days ago Cheplapharm prévoit une croissance de son chiffre d'affaires en 2025 Croissance Des Revenus Marge D'EBITDA Stabilité Financière Industrie Pharmaceutique CHEPLAPHARM
PRESS RELEASE published on 04/29/2026 at 13:00, 6 months 7 days ago CHEPLAPHARM reports Revenue Growth in the 2025 Financial Year CHEPLAPHARM reports 8.1% revenue growth reaching €1.66 billion in FY2025. EBITDA at €642.8 million with a 38.8% margin. Employee count up 2% to 799 Financial Results EBITDA Revenue Growth CHEPLAPHARM Employee Count
BRIEF published on 02/02/2026 at 15:41, 9 months 4 days ago L'émission obligataire de 950 millions d'euros de CHEPLAPHARM est un succès Stratégie Financière Emission D'obligations Refinancement Demande Des Investisseurs CHEPLAPHARM
BRIEF published on 02/02/2026 at 15:41, 9 months 4 days ago CHEPLAPHARM's Successful €950m Bond Issuance Refinancing Bond Issuance Financial Strategy Investor Demand CHEPLAPHARM
PRESS RELEASE published on 02/02/2026 at 15:36, 9 months 4 days ago Successful Refinancing: CHEPLAPHARM'S new 6.750% Bond multiple times oversubscribed CHEPLAPHARM successfully refinances with new 6.750% bond oversubscribed multiple times, enhancing financial flexibility and maturity profile Refinancing Oversubscribed Financial Flexibility CHEPLAPHARM 6.750% Bond
BRIEF published on 08/27/2025 at 13:34, 1 year 2 months ago CHEPLAPHARM Reports Stable Growth in the First Half of 2025 Pharmaceutical Industry Revenue Growth Transformation Program CHEPLAPHARM Employee Expansion
BRIEF published on 08/27/2025 at 13:34, 1 year 2 months ago CHEPLAPHARM annonce une croissance stable au premier semestre 2025 Croissance Des Revenus Industrie Pharmaceutique CHEPLAPHARM Programme De Transformation Expansion Des Employés
PRESS RELEASE published on 08/27/2025 at 13:29, 1 year 2 months ago CHEPLAPHARM with stable business in the first half of 2025 Cheplapharm AG reports stable business performance in the first half of 2025, with revenue up by 12% and EBITDA up by 24% compared to the second half of 2024 Financial Results Transformation Program Stability Acquisition Opportunities Cheplapharm AG
BRIEF published on 06/26/2025 at 10:36, 1 year 4 months ago L'obligation de 750 millions d'euros de CHEPLAPHARM connaît une forte demande et un prix attractif Obligations Confiance Des Investisseurs Médicaments Flexibilité Financière CHEPLAPHARM
BRIEF published on 06/26/2025 at 10:36, 1 year 4 months ago CHEPLAPHARM's €750M Bond Sees High Demand and Attractive Pricing Pharmaceuticals Investor Confidence Financial Flexibility Bonds CHEPLAPHARM
Published on 11/06/2026 at 13:00, 2 hours 57 minutes ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 3 hours 27 minutes ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 3 hours 27 minutes ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/06/2026 at 05:15, 10 hours 42 minutes ago Valeo and QNX Unveil A New Smart Camera Platform at CIIE, Secures Multiple Design Wins
Published on 11/06/2026 at 14:50, 1 hour 6 minutes ago New UN guide keeps people in charge of AI in smart cities
Published on 11/06/2026 at 14:45, 1 hour 12 minutes ago Ningbo Consensus on Collaborative Development released at 2026 Global Mayors Dialogue · Ningbo
Published on 11/06/2026 at 14:40, 1 hour 16 minutes ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 11/06/2026 at 09:07, 6 hours 49 minutes ago Mise à disposition de la note d'information de M14 dans le cadre de l'OPR visant les actions BOURRELIER GROUP
Published on 11/06/2026 at 09:04, 6 hours 52 minutes ago Mise à disposition de la note d'information en réponse établie par BOURRELIER GROUP initiée par M14
Published on 11/05/2026 at 18:21, 21 hours 35 minutes ago Capital et droits de vote au 31 octobre 2026
